Lumos Pharma Inc Stock Price, News & Analysis

Lumos Pharma, Inc. announced the completion of patient enrollment in its Phase 2 OraGrowtH210 and OraGrowtH212 Trials, studying the oral therapeutic LUM-201 for idiopathic pediatric growth hormone deficiency (PGHD). Primary outcome data is expected in Q4 2023. The company reported a net loss of $31.1 million for 2022, slightly higher than the prior year. R&D expenses rose to $17.9 million due to clinical trial costs, while G&A expenses increased to $15.7 million, driven by royalty and travel expenses. Lumos ended 2022 with $67.4 million in cash, projected to last until Q3 2024, while preparing for a pivotal Phase 3 trial for LUM-201.

Lumos Pharma (NASDAQ:LUMO) announced the full enrollment of its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials for LUM-201, targeting Pediatric Growth Hormone Deficiency (PGHD). A total of 82 subjects are involved in the OraGrowtH210 trial, while 22 subjects are part of the OraGrowtH212 trial, which focuses on pharmacokinetic and pharmacodynamic effects. Primary outcome data is expected in Q4 2023. Interim results from the OraGrowtH210 trial showed a mean annualized height velocity of 8.6 cm/year, consistent with expectations. If LUM-201 receives FDA approval, it could be the first oral treatment for PGHD.

Lumos Pharma, Inc. (NASDAQ:LUMO) will report its full year 2022 financial results on March 1, 2023, after market close. A conference call will follow at 4:30 PM ET to discuss these results and updates on clinical and corporate activities. The company is advancing its oral therapeutic candidate, LUM-201, for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials. LUM-201 aims to provide an alternative to injections, having received Orphan Drug Designation in both the US and EU. Investors can access the conference call via a registration link or the Lumos Pharma website.

Lumos Pharma (NASDAQ:LUMO), a biopharmaceutical company, will participate in the 12th Annual LifeSci Partners Corporate Access Event in San Francisco from January 9-11, 2023. The company is advancing its oral therapeutic candidate, LUM-201, for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials. In-person one-on-one meetings with investors will be held on January 10th and 11th. LUM-201 has received Orphan Drug Designation in the US and EU, offering a new oral treatment alternative for PGHD patients.

Lumos Pharma hosted two key opinion leaders to discuss interim data from its Phase 2 trials of LUM-201 for moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD). The KOLs shared insights on the promising oral treatment option that has the potential to improve patient compliance compared to injectable therapies. Interim results indicated an annualized growth of 8.6 cm/year at 6 months, aligning with expected outcomes. The safety and tolerability of LUM-201 appear comparable to existing treatments. This novel approach could expand treatment options for patients previously deterred by injections.

Lumos Pharma (NASDAQ:LUMO) will host a KOL webinar on December 6, 2022, discussing interim data from its Phase 2 clinical trials, OraGrowtH210 and OraGrowtH212, focused on oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD). The webinar features leading experts in pediatric endocrinology, Dr. Andrew Dauber and Dr. Fernando Cassorla. LUM-201, an innovative oral therapy, received Orphan Drug Designation from the FDA and EU, promising an alternative to traditional injections for PGHD patients. A replay will be available on Lumos Pharma's website.

Lumos Pharma (NASDAQ:LUMO) announced its participation in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in Austin, Texas. The company will host a fireside chat on November 30 at 2:00 PM (EST) and will also hold one-on-one meetings on the same day. Lumos Pharma is focused on developing LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD), currently in Phase 2 trials. The presentation can be accessed through a webcast link available on their website.

Lumos Pharma announced positive interim results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials, demonstrating a mean annualized height velocity of 8.6 cm/yr for LUM-201 at a 1.6 mg/kg/day dose. The trial is approximately 80% enrolled, with full results expected in the second half of 2023. Financially, Lumos reported a cash position of $73.7 million, estimated to sustain operations into mid-2024. R&D expenses remained stable at $4.1 million, and the net loss for Q3 2022 was $7.3 million, showing improvement from $7.5 million lost in Q3 2021.

Lumos Pharma announced that interim results for LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD), were positive in two Phase 2 trials. The OraGrowtH210 Trial, with 80% enrollment, showed a mean annualized height velocity (AHV) of 8.6 cm at six months for the 1.6 mg/kg/day dose, aligning with historical expectations of 8.3 cm. These results validate the 1.6 mg/kg/day dose for a pivotal Phase 3 trial expected in 2H 2023. No safety concerns were reported, supporting the drug's continued development.